The beneficial role of FeNO in association with GINA guidelines for titration of inhaled corticosteroids in adult asthma: A randomized study
| Autor: | Tung Truong-Thanh, Anh Vo-Thi-Kim, Dung Truong-Viet, Sy Duong-Quy, Thuc Vu-Minh, Huong Tran-Van |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Inhaled corticosteroids Nitric Oxide law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Adrenal Cortex Hormones Internal medicine Administration Inhalation Medicine Asthmatic patient Humans 030212 general & internal medicine Prospective Studies Asthma Adult patients Dose-Response Relationship Drug business.industry Patient Selection Significant difference General Medicine respiratory system medicine.disease Prognosis Gina guidelines respiratory tract diseases Breath Tests Exhalation 030220 oncology & carcinogenesis Exhaled nitric oxide Female business Biomarkers Follow-Up Studies |
| Zdroj: | Advances in medical sciences. 65(2) |
| ISSN: | 1898-4002 |
| Popis: | Purpose This study aimed to demonstrate the role of fractional concentration of exhaled nitric oxide (FeNO) in association with Global Initiative for Asthma (GINA) guidelines for treatment of adult patients with asthma. Methods It was a prospective and randomized study. The symptomatic asthmatic patients were randomly divided into two groups: GINA group (followed GINA guidelines; N = 86) or GINA + FeNO group (followed GINA guidelines + FeNO for titration of inhaled corticosteroids - ICS; N = 90). They were followed-up for 9 months. Results In GINA group, 37.2% patients had no treatment and 62.8% patients discontinued treatment vs. 40.0% and 60.0% in GINA + FeNO, respectively. After 3, 6 and 9 months of treatment, the percentage of mild, moderate and severe asthma showed no significant difference between the two groups. At 9th month, Δ moderate asthma (reduction) in GINA + FeNO group was significantly higher than in the GINA group (−22.0% vs. −11.6%; P = 0.018). The improvement of asthma control test (ACT) score was not different between the groups at 9th month (12 ± 6 vs. 10 ± 5; P > 0.05); the level of FeNO reduction in GINA + FeNO group was significantly higher than that in GINA group (−42 ± 11 vs. −35 ± 9; P = 0.022). The daily dose of ICS in GINA + FeNO group was significantly lower than that in GINA group (397 ± 171 vs. 482 ± 240 mcg and 375 ± 203 vs. 424 ± 221 mcg; respectively) at the end of 6 and 9 months. Conclusion The use of FeNO in association with GINA guidelines has a beneficial role for accurate daily dose of ICS in adult patients with asthma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect